Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1660202 | 0.98 | APP (0.71) | APPKMT2AMAPTHPGDMEN1 | |
| SCHEMBL31659799 | 0.91 | APP (0.62) | APPKMT2AMAPTHPGDMEN1 | |
| SCHEMBL26095089 | 0.91 | APP (0.67) | APPKMT2AMAPTHPGDMEN1 | |
| SCHEMBL16508317 | 0.91 | APP (0.62) | APPKMT2AMAPTHPGDMEN1 | |
| SCHEMBL10057823 | 0.90 | APP (0.61) | APPKMT2AMAPTHPGDMEN1 | |
| SCHEMBL15425076 | 0.90 | APP (0.69) | APPKMT2AMAPTHPGDMEN1 | |
| SCHEMBL17877992 | 0.87 | APP (0.61) | APPKMT2AMAPTHPGDMEN1 | |
| SCHEMBL22890844 | 0.86 | APP (0.65) | APPKMT2AMAPTHPGDMEN1 | |
| SCHEMBL31659862 | 0.86 | MAPT (0.68) | APPKMT2AMAPTHPGDMEN1 | |
| SCHEMBL16500504 | 0.86 | APP (0.65) | APPKMT2AMAPTHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592476-B2 | Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies | PROTEOTECH, INC. (US) | 2013-11-26 | — | — | US | claimed |
| US-20130012555-A1 | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes | PROTAMED, INC. | 2013-01-10 | — | — | US | claimed |
| US-20120252858-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2012-10-04 | — | — | US | claimed |
| US-20120035230-A1 | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | PROTAMED, INC. | 2012-02-09 | — | — | US | claimed |
| US-20110144124-A1 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies | PROTAMED, INC. | 2011-06-16 | — | — | US | claimed |
| EP-2328417-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF beta-AMYLOID DISEASES AND SYNUCLEINOPATHIES | Proteotech Inc. (US) | 2011-06-08 | — | — | EP | claimed |
| US-20100331380-A1 | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | PROTEOTECH INC. | 2010-12-30 | — | — | US | claimed |
| WO-2010039308-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF β-AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. (US) | 2010-04-08 | — | — | WO | claimed |
| US-20090227647-A1 | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes | PROTEOTECH INC. | 2009-09-10 | — | — | US | claimed |
| US-20090111863-A1 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | PROTAMED, INC. | 2009-04-30 | — | — | US | claimed |
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4173485-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-2307381-B1 | NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2021-01-13 | — | — | EP | disclosed |
| EP-2687513-B1 | DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2020-12-02 | — | — | EP | disclosed |
| US-10435373-B2 | Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20090227647-A1 | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes | PROTEOTECH INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227647-A1 | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes | PROTEOTECH INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090111863-A1 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | PROTAMED, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111863-A1 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | PROTAMED, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111863-A1 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | PROTAMED, INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331380-A1 | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | SNCA, PARK7, APP | APP 3/4885KMT2A 4192/4885MAPT 6/4885 |
| US-20130012555-A1 | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes | IAPP, AMY2A, IDE | APP 6/4885KMT2A 4740/4885MAPT 135/4885 |
| US-20110144124-A1 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies | PSEN2, PSEN1, MAPT | APP 36/4885KMT2A 3777/4885MAPT 3/4885 |
| US-20120035230-A1 | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | SNCA, PARK7, HTT | APP 4/4885KMT2A 4165/4885MAPT 6/4885 |
| US-20120252858-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHIES | SNCA, PARK7, APP | APP 3/4885KMT2A 4192/4885MAPT 6/4885 |
| US-20090111863-A1 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | SNCA, PARK7, APP | APP 3/4885KMT2A 4001/4885MAPT 7/4885 |
| US-20090227647-A1 | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes | IAPP, AMY2A, IDE | APP 6/4885KMT2A 4740/4885MAPT 135/4885 |
| US-10435373-B2 | Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | PARK7, APP, HYPK | APP 2/4885KMT2A 4175/4885MAPT 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.